Business
Cerus Corporation Announces Multiple In-Country Regulatory Approvals for INT200 – Next-Generation INTERCEPT Illumination Device
France and Switzerland approve INT200 for use with the INTERCEPT Blood System for Platelets and Plasma CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation
About this update from Cerus Corporation
[{"type":"text","content":"\nFrance and Switzerland approve INT200 for use with the INTERCEPT Blood System for Platelets and Plasma\n\n\n CONCORD, Calif.--(BUSINESS WIRE)--\nCerus Corporation (Nasdaq: CERS) announced today two in-country regulatory approvals for INT200, one by the French National Agency for Medicines and Health Product Safety (ANSM) and the other by the Swiss Agency for Therapeutic Products (Swissmedic).\n\n\nThe INT200, the Company’s next generation LED-based illumination device, was developed as the new foundational platform for the INTERCEPT Blood System, with input and feedback from global customers to enhance daily blood center operations. The contemporary vertical configuration is designed to improve workflow and ergonomics while freeing up bench space (three INT200 illumination devices can fit in the same footprint as a single INT100). In addition to the vertical configuration, the INT200 features touch screen navigation and intuitive software, improved tray design, intelligent scanning, and custom reporting.\n\n\nThese in-country regulatory approvals follow the CE Mark authorization received in March. In France and Switzerland, all platelet components have been treated with the INTERCEPT Blood System since 2018 and 2011, respectively.\n\n\n“We are pleased with the important in-country approvals in France and Switzerland and view these approvals as an important validation of our technology,” said Vivek Jayaraman, Cerus’ chief operating officer. “We have started the commercial rollout of this next generation platform and the early feedback continues to be very encouraging. France and Switzerland continue to be at the forefront of blood transfusion safety and we value their partnership toward ensuring the safety of the blood supply in their respective countries.”\n\n\nThe Company expects to convert its installed base of INT100s in EMEA to INT200s over the next three years.\n\n\nThe Company continues to plan for additional regulatory submissions, including a planned PMA submission to the FDA during 2026, as well as future innovation of the INTERCEPT platelet and plasma systems to leverage the INT200 platform. Further information about the INT200 can be found at https://info.interceptbloodsystem.com/intercept-illuminator-int200.\n\n\nABOUT CERUS\n\n\nCerus Corporation is dedicated solely to safeguarding the world’s blood supply and aim...